Annual report [Section 13 and 15(d), not S-K Item 405]

Note 3 - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities (Details)

v3.25.0.1
Note 3 - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Antidilutive Securities (in shares) 14,203 2,797
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities (in shares) 183 252
Restricted Stock [Member]    
Antidilutive Securities (in shares) 1,025 1,305
Warrant [Member]    
Antidilutive Securities (in shares) [1] 12,995 1,240
[1] Represents the number of shares of common stock underlying our outstanding warrants as of such dates, except for the 2,900 shares of common stock underlying the Pre-Funded Warrant issued during the year ended December 31, 2024. The weighted average number of common shares outstanding, used in the basic and diluted Net loss per share as of December 31, 2024, includes the weighted average effect of the Pre-Funded Warrant issued in connection with the September 2024 firm commitment underwritten public offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock. Refer to Note 12. Capitalization and Equity Structure — Warrants for additional information regarding the warrants.